

Wei et al.

17. Rini BI, Weinberg V, Bok R, Small EJ. Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. *J Clin Oncol* 2003;21:99–105.
18. Rini BI, Fong L, Weinberg V, Kavanaugh B, Small EJ. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor. *J Urol* 2006;175:2087–91.
19. Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. *J Natl Cancer Inst* 2014;106:dju268.
20. Serafini P, Carbley R, Noonan K, Tan G, Bronte V, Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. *Cancer Res* 2004;64:6337–43.
21. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. *J Clin Oncol* 2015;33:2780–8.
22. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. *N Engl J Med* 2010;363:411–22.
23. Wei XX, Fong L, Small EJ. Prostate Cancer Immunotherapy with Sipuleucel-T: current standards and future directions. *Expert Rev Vaccines* 2015;14:1529–41.
24. Golden EB, Chhabra A, Chachoua Adams S, Donach M, et al. Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial. *Lancet Oncol* 2015;16:795–803.
25. Pavlenko M, Roos A-K, Lundqvist A, Palmborg A, Miller AM, Ozenci V, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. *Br J Cancer* 2004;91:688–94.
26. Miller AM, Ozenci A, Kiessling R, Pisa P. Immune monitoring in a phase I trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. *J Immunother* 2005;28:389–95.
27. Kantoff PW, Schuetz T, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. *J Clin Oncol* 2010;28:1099–105.
28. Vasu C, Dogan RN, Holterman MJ, Prabhakar BS. Selective induction of dendritic cells using granulocyte macrophage-colony stimulating factor, but not fms-like tyrosine kinase receptor 3-ligand, activates thyroglobulin-specific CD4⁺/CD25⁺ T cells and suppresses experimental autoimmune thyroiditis. *J Immunol* 2003;170:5511–22.
29. Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, et al. T cell profiling reveals high CD4⁺CTLA-4⁺ T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. *Cancer Immunol Immunother* 2013;62:245–56.
30. Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, et al. Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with GVAX and ipilimumab. *J Immunother Cancer* 2014;2:31.

Cancer Immunology Research

Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer

Xiao X. Wei, Stephen Chan, Serena Kwek, et al.

Cancer Immunol Res 2016;4:948-958. Published OnlineFirst September 29, 2016.

Updated version Access the most recent version of this article at:
doi:[10.1158/2326-6066.CIR-16-0042](https://doi.org/10.1158/2326-6066.CIR-16-0042)

Supplementary Material Access the most recent supplemental material at:
<http://cancerimmunolres.aacrjournals.org/content/suppl/2016/09/28/2326-6066.CIR-16-0042.DC1>

Cited articles This article cites 30 articles, 11 of which you can access for free at:
<http://cancerimmunolres.aacrjournals.org/content/4/11/948.full#ref-list-1>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link
<http://cancerimmunolres.aacrjournals.org/content/4/11/948>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.